TATVA CHINTAN PHARMA CHEM Financial Statement Analysis
|
||
|
The Revenues of TATVA CHINTAN PHARMA CHEM have increased by 44.38% YoY .
The Earnings Per Share (EPS) of TATVA CHINTAN PHARMA CHEM has decreased by -52.55 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
TATVA CHINTAN PHARMA CHEM Last 5 Annual Financial Results
[BOM: 543321|NSE : TATVA]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹434 Cr | ₹300 Cr | ₹263 Cr | ₹206 Cr | ₹135,460,463 Cr |
| Expenses | ₹325 Cr | ₹234 Cr | ₹208 Cr | ₹172 Cr | ₹113,968,627 Cr |
| Operating Profit (Excl OI) | ₹109 Cr | ₹67 Cr | ₹55 Cr | ₹34 Cr | ₹21,491,836 Cr |
| Other Income | ₹9.02 Cr | ₹5.20 Cr | ₹1.38 Cr | ₹0.49 Cr | ₹4,782,254 Cr |
| Interest | ₹5.23 Cr | ₹4.45 Cr | ₹4.27 Cr | ₹3.95 Cr | ₹3,157,462 Cr |
| Depreciation | ₹8.18 Cr | ₹6.73 Cr | ₹4.79 Cr | ₹4.02 Cr | ₹3,583,616 Cr |
| Profit Before Tax | ₹104 Cr | ₹61 Cr | ₹48 Cr | ₹27 Cr | ₹19,510,692 Cr |
| Profit After Tax | ₹96 Cr | ₹52 Cr | ₹38 Cr | ₹21 Cr | ₹12,999,650 Cr |
| Consolidated Net Profit | ₹96 Cr | ₹52 Cr | ₹38 Cr | ₹21 Cr | ₹12,999,650 Cr |
| Earnings Per Share (Rs) | ₹20.52 | ₹43.25 | ₹26.02 | ₹47.03 | ₹25.57 |
| PAT Margin (%) | 10.73 | 22.10 | 17.40 | 14.36 | 9.96 |
| ROE(%) | 9.21 | 30.01 | 36.85 | 38.29 | 28.95 |
| ROCE(%) | 8.35 | 25.75 | 28.04 | 28.40 | 22.78 |
| Total Debt/Equity(x) | 0.33 | 0.25 | 0.54 | 0.77 | 0.97 |
Key Financials |
||
| Market Cap | : | ₹ 2,914.6 Cr |
| Revenue (TTM) | : | ₹ 393.5 Cr |
| Net Profit(TTM) | : | ₹ 30.4 Cr |
| EPS (TTM) | : | ₹ 13.0 |
| P/E (TTM) | : | 96.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| TATVA CHINTAN PHARMA CHEM | 0.4% | 11.2% | -28.7% |
| PIDILITE INDUSTRIES | -1.1% | -3.3% | 23.6% |
| SOLAR INDUSTRIES INDIA | 2.5% | 3.2% | 132% |
| SRF | -2.7% | -2% | 5% |
| GUJARAT FLUOROCHEMICALS | -1.9% | 11.9% | 7.4% |
| DEEPAK NITRITE | -1.4% | 14.2% | 31.3% |
| TATA CHEMICALS | -2.8% | 0.4% | 15.5% |
| GODREJ INDUSTRIES | NA | 10.1% | 98.3% |
| AARTI INDUSTRIES | -1.4% | 7.7% | 32.2% |
TATVA CHINTAN PHARMA CHEM Revenues
[BOM: 543321|NSE : TATVA]
| Y-o-Y | 44.38 % |
| 5 Yr CAGR | -95.77 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹434 Cr | 44.38 | |
| Mar2022 | ₹300 Cr | 14.10 | |
| Mar2021 | ₹263 Cr | 27.60 | |
| Mar2020 | ₹206 Cr | -100.00 | |
| Mar2019 | ₹135,460,463 Cr | - | |
TATVA CHINTAN PHARMA CHEM Operating Profit
[BOM: 543321|NSE : TATVA]
| Y-o-Y | 62.75 % |
| 5 Yr CAGR | -95.26 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹109 Cr | 62.75 | |
| Mar2022 | ₹67 Cr | 20.63 | |
| Mar2021 | ₹55 Cr | 62.03 | |
| Mar2020 | ₹34 Cr | -100.00 | |
| Mar2019 | ₹21,491,836 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 12.70 % |
| 5 Yr CAGR | 12.05 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 25.02% | 12.70 | |
| Mar2022 | 22.2% | 5.71 | |
| Mar2021 | 21% | 26.96 | |
| Mar2020 | 16.54% | 4.22 | |
| Mar2019 | 15.87% | - | |
TATVA CHINTAN PHARMA CHEM Profit After Tax
[BOM: 543321|NSE : TATVA]
| Y-o-Y | 83.45 % |
| 5 Yr CAGR | -94.79 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹96 Cr | 83.45 | |
| Mar2022 | ₹52 Cr | 38.30 | |
| Mar2021 | ₹38 Cr | 83.95 | |
| Mar2020 | ₹21 Cr | -100.00 | |
| Mar2019 | ₹12,999,650 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -51.45 % |
| 5 Yr CAGR | 1.88 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 10.73 % | -51.45 | |
| Mar2022 | 22.1 % | 27.01 | |
| Mar2021 | 17.4 % | 21.17 | |
| Mar2020 | 14.36 % | 44.18 | |
| Mar2019 | 9.96 % | - | |
TATVA CHINTAN PHARMA CHEM Earnings Per Share (EPS)
[BOM: 543321|NSE : TATVA]
| Y-o-Y | -52.55 % |
| 5 Yr CAGR | -5.35 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹21 | -52.55 | |
| Mar2022 | ₹43 | 66.22 | |
| Mar2021 | ₹26 | -44.67 | |
| Mar2020 | ₹47 | 83.93 | |
| Mar2019 | ₹26 | - | |
TATVA CHINTAN PHARMA CHEM Return on Capital Employed (ROCE)
[BOM: 543321|NSE : TATVA]
| Y-o-Y | -67.57 % |
| 5 Yr CAGR | -22.19 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 8.35% | -67.57 | |
| Mar2022 | 25.75% | -8.17 | |
| Mar2021 | 28.04% | -1.27 | |
| Mar2020 | 28.4% | 24.67 | |
| Mar2019 | 22.78% | - | |
TATVA CHINTAN PHARMA CHEM Share Price vs Sensex
| Current Share Price | : | ₹1,245.6 |
| Current MarketCap | : | ₹ 2,914.6 Cr |
| Updated EOD on | : | May 03,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TATVA CHINTAN PHARMA CHEM | 0.4% |
11.2% |
-28.7% |
| SENSEX | -0.6% |
0.3% |
21.8% |
TATVA CHINTAN PHARMA CHEM related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MIDSMALLCAP | 1.4% | 8.6% | 66.5% |
| S&P BSE ALLCAP | 0.4% | 3.7% | 40% |
| S&P BSE SMALL CAP | 0.2% | 9.3% | 64.7% |
| S&P BSE BASIC MATERIALS | 0.1% | 8% | 40.1% |
No NSE index found
You may also like the below Video Courses
FAQ about TATVA CHINTAN PHARMA CHEM Financials
How the annual revenues of TATVA CHINTAN PHARMA CHEM have changed ?
The Revenues of TATVA CHINTAN PHARMA CHEM have increased by 44.38% YoY .
How the Earnings per Share (EPS) of TATVA CHINTAN PHARMA CHEM have changed?
The Earnings Per Share (EPS) of TATVA CHINTAN PHARMA CHEM has decreased by -52.55 % YoY .
Check out Intrinsic Value of Peers of TATVA CHINTAN PHARMA CHEM
Compare Stock Analytics of Peers of TATVA CHINTAN PHARMA CHEM
PIDILITE INDUSTRIES LTD vs SOLAR INDUSTRIES INDIA LTD vs SRF LTD
GUJARAT FLUOROCHEMICALS LTD vs DEEPAK NITRITE LTD vs
PIDILITE INDUSTRIES LTD vs SOLAR INDUSTRIES INDIA LTD vs SRF LTD
GUJARAT FLUOROCHEMICALS LTD vs DEEPAK NITRITE LTD vs
